CYP3A7 and breast cancer: Based on the combined evidence of prospective studies of premenopausal hormone levels and breast cancer risk, lifetime lower levels of E1 and E2 of ∼45% and 27% in carriers of the CYP3A7*1C allele would be predicted to result in a substantial reduction in risk for these individuals.